Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
Ovaries01:26

Ovaries

The ovaries are roughly the size of almonds and measure approximately 2 to 3 centimeters in length. These paired structures are situated within the pelvic region and are anchored by the mesovarium—a peritoneal extension that also connects them to the wider structure of the broad ligament. The support system extends to the suspensory ligament, housing blood and lymphatic vessels. In addition, the ovarian ligament tethers the ovaries to the uterus.
On the ovarian surface, a layer of cuboidal...
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Whole genome sequencing of pre-treatment and post-treatment locally advanced rectal cancer using long and short read technologies.

Scientific reports·2026
Same author

RETRACTED: Richards et al. Protein Tyrosine Phosphatase Non-Receptor 11 (<i>PTPN11</i>/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). <i>Int. J. Mol. Sci.</i> 2023, <i>24</i>, 10545.

International journal of molecular sciences·2026
Same author

A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer.

Scientific reports·2026
Same author

Case Report: Whole-genome sequencing of urothelial carcinoma in an adult patient with CLOVES syndrome reveals a lack of <i>PIK3CA</i> mutation and a genomic landscape consistent with urothelial carcinoma.

Frontiers in oncology·2026
Same author

Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer.

BMC cancer·2026
Same author

Dose Adjusted Neoadjuvant Paclitaxel, Carboplatin, Trastuzumab and Pertuzumab in Women With HER2 Positive Early Breast Cancer.

Clinical breast cancer·2025

関連する実験動画

Updated: Jun 19, 2026

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

卵巣がんは卵巣がんである.

Bryan T Hennessy1, Robert L Coleman, Maurie Markman

  • 1Department of Gynecologic Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Lancet (London, England)
|October 2, 2009
PubMed
まとめ

標準的な上皮性卵巣がんの治療には,手術と化学療法が含まれます. 初期治療は効果的ですが,再発は一般的であり,患者の生存率と結果を改善するための新しい治療法の研究が必要になります.

科学分野:

  • 婦人科腫瘍学 婦人科腫瘍学
  • 医療腫瘍学 医療腫瘍学
  • 外科腫瘍学外科腫瘍学

背景:

  • エピテリア性卵巣がん (EOC) の管理は,通常,外科的ステージ設定,腫瘍解体,および化学療法 (カルボプラチン/パクリタキセル) を含む.
  • <1cmの残留疾患まで最適の外科的脱栓は,より良い患者のアウトカムと相関しています.
  • ほとんどの患者 (75%) が進行した疾患 (第3段階/第4段階) を有しており,初期応答率>80%にもかかわらず,再発はほぼ普遍的です.

研究 の 目的:

  • エピテリア性卵巣がんの標準的な管理をレビューする.
  • 先進段階での腫瘍再発の課題を強調する.
  • 患者のアウトカムを改善するための潜在的な将来の治療戦略について議論する.

主な方法:

  • エピテリア性卵巣がんに対する標準的な外科および化学療法プロトコルのレビュー.
  • 予後要因の分析,手術によるデブルッキングの範囲を含む.
  • 新興の治療方法と薬剤投与技術の探索.

主要な成果:

  • 標準的な治療は初期に効果があるが,その後15ヶ月以内に腫瘍が再発することが多い.
  • セカンドラインの治療は症状を緩和し,生活の質を向上させることができますが,治癒ではありません.

さらに関連する動画

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

関連する実験動画

Last Updated: Jun 19, 2026

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

  • 腫瘍の再発は,先端の上皮性卵巣がんにおける重要な課題であり続けています.
  • 結論:

    • スクリーニングの進歩,分子病原性の理解,標的療法 (ベバシズマブなど) および腹腔内投与薬の投与は,アウトカムを改善するために不可欠です.
    • 将来の研究は,治療抵抗性を克服し,再発を防ぐための新しい治療戦略に焦点を当てなければなりません.
    • エピテリア性卵巣がんの患者のアウトカムを改善することは,早期発見と高度な治療方法を組み合わせた統合的アプローチを通じて予想されます.